De-escalating and discontinuing disease-modifying therapies in multiple sclerosis
Brain · 13.05.2025 · 148 (5) · 1459-1478
DOI: 10.1093/brain/awae409 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain, online erschienen am 21.12.2024. Verfasst von Géraldine Androdias und 43 weiteren Autor:innen. Beteiligte Einrichtung: Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Centre de Ressources, Recherche et Compétence sur la Scl…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Committee for Treatment and Research in Multiple Sclerosis.
Abstract (Originalsprache)
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs after disease onset is associated with a better long-term prognosis. However, the question of when and how to de-escalate or discontinue DMTs remains open and critical. This topic was discussed during an international focused workshop organized by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in 2023. The aim was to review the current evidence on the rationale for, and the potential pitfalls of, treatment de-escalation in MS. Several clinical scenarios emerged, mainly driven by a change in the benefit-risk ratio of DMTs over the course of the disease and with ageing. The workshop also addressed the issue of de-escalation by the type of DMT used and in specific situations, including pregnancy and paediatric onset MS. Finally, we provide practical guidelines for selecting appropriate patients, defining de-escalation and monitoring modalities and outlining unmet needs in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Centre de Ressources, Recherche et Compétence sur la Sclérose en Plaques, Hôpital Neurologique Pierre Wertheimer, Hospices Civ…
- Clinique de la Sauvegarde, Ramsay Santé, Lyon 69009, France.
- Department of Neurology with Institute of Translational Neurology, University and University Hospital Münster, Münster 48149, Germany.
- Department of Neurology, Multiple Sclerosis Center, Pitié-Salpêtrière Hospital, AP-HP, Paris 75013, France.
- Departmente NEUROFARBA, University of Florence, Florence 50139, Italy.
- IRCCS Fondazione Don Carlo Gnocchi, Florence 50143, Italy.
ORCID-Profile: Géraldine Androdias, Jan D Lünemann, Arlette L Bruijstens, Gabriel Bsteh, Alvaro Cobo-Calvo, Cristina Granziera, Yael Hacohen, Jaume Sastre-Garriga, Frauke Zipp, Bruno Stankoff
Förderung
- European Committee for Treatment and Research in Multiple Sclerosis
Zitieren
APA
Androdias, G., Lünemann, J. D., Maillart, E., Amato, M. P., Audoin, B., Bruijstens, A. L., Bsteh, G., Butzkueven, H., Ciccarelli, O., Cobo-Calvo, A., Derfuss, T., Di Pauli, F., Edan, G., Enzinger, C., Geraldes, R., Granziera, C., Hacohen, Y., Hartung, H. P., Hynes, S., …, & Stankoff, B. (2025). De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain, 148(5), 1459-1478. https://doi.org/10.1093/brain/awae409
Vancouver
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain. 2025;148(5):1459-1478. doi:10.1093/brain/awae409
BibTeX
@article{Androdias2025,
author = {Androdias, Géraldine and Lünemann, Jan D and Maillart, Elisabeth and Amato, Maria Pia and Audoin, Bertrand and Bruijstens, Arlette L and Bsteh, Gabriel and Butzkueven, Helmut and Ciccarelli, Olga and Cobo-Calvo, Alvaro and Derfuss, Tobias and Di Pauli, Franziska and Edan, Gilles and Enzinger, Christian and Geraldes, Ruth and Granziera, Cristina and Hacohen, Yael and Hartung, Hans-Peter and Hynes, Sinéad and Inglese, Matilde and Kappos, Ludwig and Kuusisto, Hanna and Langer-Gould, Annette and Magyari, Melinda and Marignier, Romain and Montalban, Xavier and Mycko, Marcin P and Nourbakhsh, Bardia and Oh, Jiwon and Oreja-Guevara, Celia and Piehl, Fredrik and Prosperini, Luca and Sastre-Garriga, Jaume and Sellebjerg, Finn and Selmaj, Krzysztof and Siva, Aksel and Tallantyre, Emma and van Pesch, Vincent and Vukusic, Sandra and Weinstock-Guttman, Bianca and Zipp, Frauke and Tintoré, Mar and Iacobaeus, Ellen and Stankoff, Bruno},
title = {De-escalating and discontinuing disease-modifying therapies in multiple sclerosis},
journal = {Brain},
year = {2025},
volume = {148},
number = {5},
pages = {1459--1478},
doi = {10.1093/brain/awae409}
}
EUVIMED